Pregnant women with STI, including trichomonas infection may result in premature or low birth weight. Symptoms and final diagnosis do not always correlate and treatment may not resolve symptoms.Vaginitis symptoms or suggestive history of STI and the Gen-Probe TMA APTIMA assay for Trichomoniasis detected a prevalence of 5.1% in a current study of 766 patients versus currently available methodologies that indicate a lower rate of 3.2%.
Trichomonas vaginalis (TV) is primarily asymptomatic and associated with concurrent STIs in the general population. Screening for Trichomonas is limited today in part due to the shortfalls of current testing techniques. Most testing currently is done via culture methods, which are slower and less sensitive than molecular tests, or "wet mount," which requires the microscopic examination of a sample shortly after it is collected.
Aptima by Transcription-Mediated Amplification (TMA)
3.0 mL ThinPrep® PAP media or SurePath™ TestPack solution
1.0 mL liquid cytology media media transferred to APTIMA specimen transfer (GREEN) tube
One cervical swab collected with APTIMA Unisex Swab Specimen Collection Kit (blue swab)
20.0-30.0 mL (first catch) urine (female) collected in preservative-free urine collection cup or 2.0 mL urine transferred to APTIMA urine specimen transport (YELLOW) tube
Transport and store all specimens at 2-30°C
Insufficient specimen volume
No swab in transport tube
Urine specimens >24 hours old unless transferred to APTIMA urine transport (YELLOW) tube
The APTIMA Trichomonas vaginalis Assay is an in vitro qualitative nucleic acid amplification test cleared by the FDA for the detection of ribosomal RNA (rRNA) from Trichomonas vaginalis to aid in the diagnosis of trichomoniasis using the TIGRIS DTS System.
The assay may be used to test specimens from symptomatic or asymptomatic women.
APTIMA s a trademark of Gen-Probe, Inc.
ThinPrep is a registered trademark of Cytyc Corporation